Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study*

Greenlee, 2000, Cancer statistics, 2000, CA Cancer J Clin, 50, 7, 10.3322/canjclin.50.1.7 Miller, 1994, Nonmelanoma skin cancer in the United States: incidence, J Am Acad Dermatol, 30, 774, 10.1016/S0190-9622(08)81509-5 Puizina-Ivi, 1999, Histopathologic variants of basal cell carcinoma correlation with sex, age and localization, J Med Syst, 23, 389, 10.1023/A:1020533318323 Bastiaens, 1998, Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors, J Invest Dermatol, 110, 880, 10.1046/j.1523-1747.1998.00217.x Jaramillo-Ayerbe, 2000, Cryosurgery in difficult to treat basal cell carcinoma, Int J Dermatol, 39, 223, 10.1046/j.1365-4362.2000.00952.x McCormack, 1997, Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indication of differing causes, Arch Dermatol, 133, 593, 10.1001/archderm.1997.03890410049006 Silverman, 1991, Recurrence rates of treated basal cell carcinomas. Part 1: overview; Part 2: curettage-electrodesiccation, J Dermatol Surg Oncol, 17, 713-8 Silverman, 1992, Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision, J Dermatol Surg Oncol, 18, 471, 10.1111/j.1524-4725.1992.tb03307.x Robinson, 1987, Risk of developing another basal cell carcinoma: a 5-year prospective study, Cancer, 60, 118, 10.1002/1097-0142(19870701)60:1<118::AID-CNCR2820600122>3.0.CO;2-1 Slade, 1998, Imiquimod 5% cream (Aldara), Exp Opin Invest Drugs, 7, 437, 10.1517/13543784.7.3.437 Edwards, 1990, The effect of intralesional interferon gamma on basal cell carcinomas, J Am Acad Dermatol, 22, 496, 10.1016/0190-9622(90)70070-X Edwards, 1990, The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas, Arch Dermatol, 126, 1029, 10.1001/archderm.1990.01670320053006 Cornell, 1990, Intralesional interferon therapy for basal cell carcinoma, J Am Acad Dermatol, 23, 694, 10.1016/0190-9622(90)70276-N Beutner, 1999, Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream, J Am Acad Dermatol, 416, 1002, 10.1016/S0190-9622(99)70261-6 Fitzpatrick, 1988, The validity and practicality of sun-reactive skin types I through VI, Arch Dermatol, 124, 869, 10.1001/archderm.1988.01670060015008 Holmkvist, 1999, Incidence of residual basal cell carcinoma in patients who appear tumor free after biopsy, J Am Acad Dermatol, 41, 600 Kagy, 2000, The use of imiquimod 5% cream for the treatment of a superficial basal cell nevus syndrome patient, Dermatol Surg, 26, 577, 10.1046/j.1524-4725.2000.00003.x Marks, 2001, Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial, J Am Acad Dermatol, 44, 807, 10.1067/mjd.2001.113689 Telfer, 1999, Guidelines for the management of basal cell carcinoma, Br J Dermatol, 141, 415, 10.1046/j.1365-2133.1999.03033.x Thissen, 1999, A systematic review of treatment modalities for primary basal cell carcinomas, Arch Dermatol, 135, 1177, 10.1001/archderm.135.10.1177 Robinson, 2000, Recurrent basal cell carcinoma after incomplete resection, Arch Dermatol, 136, 1318, 10.1001/archderm.136.11.1318 Chiller, 2000, Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer, Arch Dermatol, 136, 1327, 10.1001/archderm.136.11.1327